Amarin Corp. (AMRN) – StreetInsider.com Reports
-
After-hours movers: GitLab surges on earnings, EyePoint adds to intra-day gains
-
Sarissa Capital Believes Amarin (AMRN) Stock Is Meaningfully Undervalued, Increases Its Ownership
-
Catalyst Pharmaceuticals (CPRX) Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
-
JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
-
Amarin Corp. (AMRN) Reports New REDUCE-IT Data Showing VASCEPA Associated with 29 Percent Relative Risk Reduction Compared with Placebo
-
Amarin Corp. (AMRN) Reports In-Line Q3 EPS
-
Jefferies Downgrades Amarin Corporation (AMRN) to Hold
-
Amarin's (AMRN) new CEO buys $300k in stock as promised
-
Amarin (AMRN) Provides Pricing & Reimbursement Updates for VAZKEPA in The Netherlands and Italy
-
Amarin (AMRN) And Neopharm Enter Exclusive Commercialization Agreement for VAZKEPA in Israel
-
Amarin Corp. (AMRN) VAZKEPA accepted by the Scottish Medicines Consortium
-
Amarin Corp. (AMRN) Files $100M Mixed Shelf
-
Amarin Corp. (AMRN) Tops Q2 EPS by 5c
-
Amarin Corp. (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress
-
Amarin Corp. (AMRN) Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA
-
Amarin Corporation (AMRN) PT Lowered to $1.25 at Northland Capital Markets
-
Amarin (AMRN) PT Lowered to $1 at Goldman Sachs, "stock to remain range bound until execution improves"
-
Amarin (AMRN) Appoints Patrick Holt as President and CEO
-
Amarin Corp. (AMRN) Announces Organizational Restructuring
-
Amarin (AMRN) Announces Vascepa Approved in Saudi Arabia to Reduce Cardiovascular Risk
-
Amarin's (AMRN) Partner EddingPharm Receives Regulatory Approval for Vascepa in China
-
Amarin Corp. (AMRN) Tops Q1 EPS by 5c
-
Amarin Corp. (AMRN) Appoints Aaron Berg Interim CEO
-
Amarin Corp. (AMRN) Announces VAZKEPA Approved by Israel's Ministry of Health
-
Amarin Corp. (AMRN) President and CEO Karim Mikhail to Resign
-
Amarin Corp. (AMRN) Says Reconstituted Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA
-
Amarin Corp. (AMRN) Announces Board Departures
-
Amarin (AMRN) Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
-
Amarin Corp. (AMRN) Tops Q4 EPS by 3c
-
Sarissa Capital Wins Proxy Contest Against Amarin (AMRN) by Huge Landslide
-
Amarin Corp. (AMRN) says shareholders have voted to elect all seven of Sarissa’s nominees
-
Amarin Corp. (AMRN) and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA in Australia and New Zealand
-
Amarin (AMRN) Comments on Sarissa’s "Latest Misstatements"
-
Amarin Corp. (AMRN) to Present New Data Evaluating VASCEPA/VAZKEPA
-
Amarin Corp. (AMRN) Urges Shareholders to Vote "Against" Sarissa's Harmful Proposals at Upcoming General Meeting
-
Sarissa Capital Urges Amarin (AMRN) Shareholders to Vote for Change and Remake Amarin for Shareholders
-
Sarissa Capital Response to Amarin (AMRN)
-
Sarissa Capital Highlights Amarin’s (AMRN) Inaccurate and Misleading Statements
-
Amarin Corp. (AMRN) Mails Letter to Shareholders Highlighting New Board and Superior Leadership
-
Amarin Corp. (AMRN) Files Definitive Proxy Materials and Mails Letter to Shareholders
-
Amarin Corp. (AMRN) Announces VAZKEPA Approved By Medsafe In New Zealand
-
Sarissa Capital submits notice on Amarin Corp. (AMRN) for special meeting to add director and remove Chairman
-
Amarin Corp. (AMRN) Prelim. Q4 Revenue Tops Consensus
-
Amarin (AMRN) Appoints Murray W. Stewart to its Board
-
Jefferies Upgrades Amarin Corporation (AMRN) to Buy
-
Amarin Corp. (AMRN) Announces VAZKEPA Receives Regulatory Approval in Switzerland
-
Amarin Corp. (AMRN) Announces VAZKEPA Approved in Australia
-
Amarin Corp. (AMRN) Appoints Adam Berger and Geraldine Murphy to its Board
-
Amarin (AMRN) Board of Directors Issues Statement in Response to Sarissa
-
Amarin Corp. (AMRN) Responds to Sarissa
Back to AMRN Stock Lookup